Risky Business: Most Cancer Drugs Don ' t Reach the Market Risky Business: Most Cancer Drugs Don ' t Reach the Market

A new analysis finds that a cancer drug tested in a phase 1 trial has about a 6% chance of eventual FDA approval, but some factors may up those odds.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news